Should You Buy Humana Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Humana Inc. (HUM) scores a robust 7.6/10 on our 32-signal Quality of Company framework. At the current market price of $396.62 and a $47.6B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 1 of 6 CirclFi valuation models project upside for Humana Inc. (HUM) at $396.62 — the model consensus leans bearish, with a Quality Score of 7.6/10 and Value-Trap risk of 13/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Humana Inc. (HUM) in 2026?
What Is the Bull Case vs the Bear Case for Humana Inc. (HUM)?
| Bull case — $514.06 target (+29.6%) | Bear case — $87.03 target (-78.1%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Humana Inc.'s rating of 7.6/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $87.03 (-78.1%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $514.06 (+29.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +107.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: orphan drug designation could provide meaningful support for Humana Inc.'s revenue and margin trajectory in the Healthcare Plans space. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Humana Inc. and its Healthcare Plans peers. |
How Does HUM Compare to Its Healthcare Plans Peers?
Valuation data pages: MOH · CVS · CI · CNC · UNH · ALHC · MRAI · ELV · PGNY · PFHO
Which Other Stocks Score Like HUM on Quality?
Closest companies to HUM’s Quality of Company score of 7.6/10, across all industries.
- TXG — 10x Genomics, Inc. (QOC 7.6) · analysis
- BIPC — Brookfield Infrastructure Corporation (QOC 7.6) · analysis
- QSR — Restaurant Brands International Inc. (QOC 7.6) · analysis
- MHK — Mohawk Industries, Inc. (QOC 7.6) · analysis
- APTV — Aptiv PLC (QOC 7.6) · analysis
- LOAR — Loar Holdings Inc. (QOC 7.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Humana Inc. (HUM) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Humana Inc. at $396.62. 5/6 models flag overvaluation, median fair value sits at $217.77 (-45.1%), and the risk-reward profile appears unfavorable. Quality at 7.6/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Humana Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About HUM Stock?
Should I buy HUM stock right now?
Based on CirclFi's multi-model analysis, 1 of 6 models see upside for HUM at $396.62. The models are divided, which means the investment case depends heavily on your assumptions about Humana Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Humana Inc.?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (491% spread), signaling high uncertainty; general market and sector-specific risks affecting Healthcare Plans companies. Always diversify and consult a financial advisor.
How does HUM compare to its competitors?
Among Healthcare Plans peers, HUM holds a Quality Score of 7.6/10. Comparable companies include MOH (QOC 7.7), CVS (QOC 7.4), CI (QOC 7.9). The relative ranking helps investors identify whether HUM offers better fundamental quality than alternatives in the same sector.
Is HUM a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. HUM's Quality Score of 7.6/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy HUM at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $87.03 to $514.06. At $396.62, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for HUM.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad